Innovative Research Solutions for Mice & Rats – Kent Scientific provides integrated, modular solutions for small animal pre-clinical research and drug discovery advancement. Select a system type or search our products to find the right Kent Scientific solution for your lab. @ CIÊNCIA -> Promissora, técnica Crispr é aplicada pela 1ª vez em pacientes com câncer Crispr Therapeutics e sua parceira Vertex Pharmaceuticals lideram a corrida da edição genética – Por Tatiana Darie, da Bloomberg access_time 17 abr 2019, 10h12


Do the downloads!! Share!! The diffusion of very important information and knowledge is essential for the world progress always!! Thanks!
!

  • – > Mestrado – Dissertation – Tabelas, Figuras e Gráficos – Tables, Figures and Graphics´´My´´ Dissertation @ #Innovation #energy #life #health #Countries #Time #Researches #Reference #Graphics #Ages #Age #Mice #People #Person #Mouse #Genetics #PersonalizedMedicine #Diagnosis #Prognosis #Treatment #Disease #UnknownDiseases #Future #VeryEfficientDrugs #VeryEfficientVaccines #VeryEfficientTherapeuticalSubstances #Tests #Laboratories #Investments #Details #HumanLongevity #DNA #Cell #Memory #Physiology #Nanomedicine #Nanotechnology #Biochemistry #NewMedicalDevices #GeneticEngineering #Internet #History #Science #World

Pathol Res Pract. 2012 Jul 15;208(7):377-81. doi: 10.1016/j.prp.2012.04.006. Epub 2012 Jun 8.

The influence of physical activity in the progression of experimental lung cancer in mice

Renato Batista Paceli 1Rodrigo Nunes CalCarlos Henrique Ferreira dos SantosJosé Antonio CordeiroCassiano Merussi NeivaKazuo Kawano NagaminePatrícia Maluf Cury


Impact_Fator-wise_Top100Science_Journals

GRUPO_AF1GROUP AFA1 – Aerobic Physical Activity – Atividade Física Aeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

GRUPO AFAN 1GROUP AFAN1 – Anaerobic Physical ActivityAtividade Física Anaeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

GRUPO_AF2GROUP AFA2 – Aerobic Physical ActivityAtividade Física Aeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

GRUPO AFAN 2GROUP AFAN 2 – Anaerobic Physical ActivityAtividade Física Anaeróbia´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

Slides – mestrado´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

CARCINÓGENO DMBA EM MODELOS EXPERIMENTAIS

DMBA CARCINOGEN IN EXPERIMENTAL MODELS

Avaliação da influência da atividade física aeróbia e anaeróbia na progressão do câncer de pulmão experimental – Summary – Resumo´´My´´ Dissertation Faculty of Medicine of Sao Jose do Rio Preto

https://pubmed.ncbi.nlm.nih.gov/22683274/

Abstract

Lung cancer is one of the most incident neoplasms in the world, representing the main cause of mortality for cancer. Many epidemiologic studies have suggested that physical activity may reduce the risk of lung cancer, other works evaluate the effectiveness of the use of the physical activity in the suppression, remission and reduction of the recurrence of tumors. The aim of this study was to evaluate the effects of aerobic and anaerobic physical activity in the development and the progression of lung cancer. Lung tumors were induced with a dose of 3mg of urethane/kg, in 67 male Balb – C type mice, divided in three groups: group 1_24 mice treated with urethane and without physical activity; group 2_25 mice with urethane and subjected to aerobic swimming free exercise; group 3_18 mice with urethane, subjected to anaerobic swimming exercise with gradual loading 5-20% of body weight. All the animals were sacrificed after 20 weeks, and lung lesions were analyzed. The median number of lesions (nodules and hyperplasia) was 3.0 for group 1, 2.0 for group 2 and 1.5-3 (p=0.052). When comparing only the presence or absence of lesion, there was a decrease in the number of lesions in group 3 as compared with group 1 (p=0.03) but not in relation to group 2. There were no metastases or other changes in other organs. The anaerobic physical activity, but not aerobic, diminishes the incidence of experimental lung tumors.

Copyright © 2012 Elsevier GmbH. All rights reserved.

https://www.kentscientific.com/

https://exame.abril.com.br/ciencia/promissora-tecnica-crispr-e-aplicada-pela-1a-vez-em-pacientes-com-cancer/?fbclid=IwAR34-HQ8aFSdyZmhR6kxTTRmnOvSrTrBDmYO5llSjg0bdlH3qiOkE1VF0zI

search There are no items in your cart. View Products ›888-572-8887

Innovative Research Solutions for Mice & Rats

Kent Scientific provides integrated, modular solutions for small animal pre-clinical research and drug discovery advancement. Select a system type or search our products to find the right Kent Scientific solution for your lab.

An innovative low-flow anesthesia system that is safe for you and safer for your animals

View the SomnoSuite

A physiological monitoring system you configure to meet your research needs

Build Your PhysioSuite

A non-invasive, high throughput system for measuring blood pressure

View CODA HT

Additional Featured Products

What’s New

Kent Resources

Visit here often to learn about Kent Scientific products in use, FAQs, whitepaper validations, research partners and moreLearn More

Catch us at Experimental Biology 2019

April 6 – 9, 2019: Orlando, FL

Booth #828

Check out or newest products and speak to a specialist to see how Kent Scientific’s solutions may be right for your research.See Event Details

Kent​Connects

Building a Better Research Mouse 3/25/2019 Read More

Kent​Gives​Back

Proudly supporting the research community through product giveaways, travel awards and the sponsorship of professional conferences, meetings and educational programs.Learn More

Email Signup

Facebook
LinkedIn
YouTube
Twitter

Kent Scientific Corporation
1116 Litchfield Street
Torrington, CT 06790, USA Toll Free: (888) 572-8887
Local: (860) 626-1172
Fax: (860) 626-1179Web Solutions © 2006 – 2019 Kent Scientific Corporation. All rights reserved.

CIÊNCIA

Promissora, técnica Crispr é aplicada pela 1ª vez em pacientes com câncer

Crispr Therapeutics e sua parceira Vertex Pharmaceuticals lideram a corrida da edição genética

Por Tatiana Darie, da Bloombergaccess_time 17 abr 2019, 10h12 more_horiz

Cirurgia genética

Crispr: técnica de edição genética começa a ser testada no tratamento de câncer (sxc.hu/Reprodução)

Médicos do Centro de Câncer Abramson, da Universidade da Pensilvânia, realizaram uma infusão com um medicamento à base de Crispr em dois pacientes com câncer, em outro teste em humanos com a promissora tecnologia de edição de genes.

Ambos os pacientes com câncer haviam tido uma recaída antes do início do estudo clínico. Um paciente tem mieloma múltiplo e, o outro, sarcoma, disse o representante da Penn Medicine, John Infanti, em e-mail. O teste clínico é financiado pelo Instituto Parker de Imunoterapia para o Câncer, do bilionário Sean Parker, e pela empresa de capital fechado Tmunity Therapeutics, disse.

1 Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s